We are a clinical-stage immuno-oncology company and a leader in the field of
neoantigen-targeted therapies, dedicated to transforming the treatment of cancer
by directing the immune system towards neoantigens. Genetic mutations, which are
a hallmark of cancer, can result in specific immune targets called neoantigens.
The presence of neoantigens in cancer cells and their absence in normal cells
makes them compelling, untapped targets for cancer therapy. By directing the
immune system towards these targets, we believe our neoantigen-targeted
therapies will offer a new level of patient and tumor specificity in the field
of cancer immunotherapy that will drive a strong risk-benefit profile to
dramatically improve patient outcomes.
Our ambition is to lead a paradigm shift in the treatment of cancer patients
towards an era of truly personal immuno-oncology therapies.
News about NTGN
IPO Update: Hookipa Pharma Readies $100 Million IPO
Quick Take Hookipa Pharma (HOOK) has filed proposed terms to raise $100 million in a U.S. IPO, per an amended registration statement. Hookipa is advancing a pipeline of immunotherapeutics for infectious diseases and cancers. HOOK has generated pro...Read More>>>
Neon Therapeutics Inc (NTGN) Given Consensus Rating of “Strong Buy” by Analysts
Shares of Neon Therapeutics Inc (NASDAQ:NTGN) have been given a consensus broker rating score of 1.13 (Strong Buy) from the four analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock wi...Read More>>>
DAFNA Capital Management LLC Takes $630,000 Position in Neon Therapeutics Inc (NTGN)
DAFNA Capital Management LLC acquired a new position in shares of Neon Therapeutics Inc (NASDAQ:NTGN) in the 2nd quarter, Holdings Channel reports. The fund acquired 50,000 shares of the company’s stock, valued at approximately $630,000. Othe...Read More>>>
Somewhat Critical Media Coverage Somewhat Unlikely to Affect Neon Therapeutics (NTGN) Stock Price
News stories about Neon Therapeutics (NASDAQ:NTGN) have trended somewhat negative recently, according to Accern Sentiment. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. ...Read More>>>
The Week Ahead: Senate Weighs Sprint-T-Mobile Merger, Nike Earnings And A Slew Of IPOs
Below is a list of notable corporate events for the week beginning June 25. Note, this list is not comprehensive and all dates are subject to change. All times are ET. Monday Notable Earnings Carnival Corporation (NYSE: CCL) Q2 premarket FDA/Biotec...Read More>>>